Samsara BioCapital’s KalVista Pharmaceuticals KALV Stock Holding History

Samsara BioCapital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-67,270	Closed	-$1.28K	–	49
2020 Q4	$1.28K	Sell	67,270 -16,817	-20%	-$288K	0.13%	37
2020 Q3	$1.06M	Sell	84,087 -84,087	-50%	-$1.05M	0.3%	33
2020 Q2	$2.04M	Hold	168,174	–	–	0.65%	24
2020 Q1	$1.29M	Buy	168,174 +49,674	+42%	+$670K	0.74%	22
2019 Q4	$2.11M	Hold	118,500	–	–	1.01%	17
2019 Q3	$1.38M	Hold	118,500	–	–	0.94%	16
2019 Q2	$2.63M	Hold	118,500	–	–	1.73%	12
2019 Q1	$3.39M	Sell	118,500 -31,500	-21%	-$683K	2.66%	10
2018 Q4	$2.96M	Buy	+150,000	New	+$3.02M	2.84%	8

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Samsara BioCapital's KALV Position: Q1 2021 in Review

Samsara BioCapital sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 67,270 shares — an estimated $1.28K sold.

Samsara BioCapital first reported a position in KALV in Q4 2018 and held it in 9 quarters. The position peaked at $3.39M in Q1 2019. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

Samsara BioCapital reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Samsara BioCapital sold 67,270 KalVista Pharmaceuticals shares in Q1 2021, an estimated $1.28K.
Samsara BioCapital first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 9 quarters.
Samsara BioCapital's KalVista Pharmaceuticals position peaked at $3.39M in Q1 2019.
117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.